Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-10-18

AUTHORS

Luuk Wieske, Duncan Smyth, Michael P. Lunn, Filip Eftimov, Charlotte E. Teunissen

ABSTRACT

Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. More... »

PAGES

1-17

References to SciGraph publications

  • 2020-06-15. A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy in SCIENTIFIC REPORTS
  • 2021-05-18. A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study in ALZHEIMER'S RESEARCH & THERAPY
  • 2018-08-31. Neurofilaments as biomarkers in neurological disorders in NATURE REVIEWS NEUROLOGY
  • 2018-06-26. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy in BREAST CANCER RESEARCH AND TREATMENT
  • 2014-01-20. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study in CRITICAL CARE
  • 2007-01-02. Evidence for a wide extra-astrocytic distribution of S100B in human brain in BMC NEUROSCIENCE
  • 2020-05-14. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy in SCIENTIFIC REPORTS
  • 2017-08-10. Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies in SCIENTIFIC REPORTS
  • 2012-04-22. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain–Barré syndrome in NEUROLOGICAL SCIENCES
  • 2021-05-26. Seven day pre-analytical stability of serum and plasma neurofilament light chain in SCIENTIFIC REPORTS
  • 2015-12-23. The epidemiology and risk factors of chronic polyneuropathy in EUROPEAN JOURNAL OF EPIDEMIOLOGY
  • 2019-01-31. Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants in SCIENTIFIC REPORTS
  • 2021-04-02. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients in JOURNAL OF NEUROLOGY
  • 2013-11-12. Increased Circulating Th17 Cell Populations and Elevated CSF Osteopontin and IL-17 Concentrations in Patients with Guillain-Barré Syndrome in JOURNAL OF CLINICAL IMMUNOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s13311-021-01136-0

    DOI

    http://dx.doi.org/10.1007/s13311-021-01136-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1141955389

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34661878


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Neurosciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.484519.5", 
              "name": [
                "Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wieske", 
            "givenName": "Luuk", 
            "id": "sg:person.01221612201.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221612201.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UCL Queen Square Institute of Neurology, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.83440.3b", 
              "name": [
                "Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK", 
                "UCL Queen Square Institute of Neurology, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Smyth", 
            "givenName": "Duncan", 
            "id": "sg:person.016020033434.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016020033434.82"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UCL Queen Square Institute of Neurology, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.83440.3b", 
              "name": [
                "Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK", 
                "UCL Queen Square Institute of Neurology, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lunn", 
            "givenName": "Michael P.", 
            "id": "sg:person.013434667454.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013434667454.77"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.484519.5", 
              "name": [
                "Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Eftimov", 
            "givenName": "Filip", 
            "id": "sg:person.0634111633.10", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634111633.10"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.484519.5", 
              "name": [
                "Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Teunissen", 
            "givenName": "Charlotte E.", 
            "id": "sg:person.01113740141.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113740141.22"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/s41598-020-64511-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1127595131", 
              "https://doi.org/10.1038/s41598-020-64511-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-018-37572-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1111775406", 
              "https://doi.org/10.1038/s41598-018-37572-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-020-66815-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1128483154", 
              "https://doi.org/10.1038/s41598-020-66815-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10072-012-1092-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030217645", 
              "https://doi.org/10.1007/s10072-012-1092-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00415-021-10537-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1136872557", 
              "https://doi.org/10.1007/s00415-021-10537-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-021-90639-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138362468", 
              "https://doi.org/10.1038/s41598-021-90639-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13195-021-00841-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138157330", 
              "https://doi.org/10.1186/s13195-021-00841-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41582-018-0058-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1106465735", 
              "https://doi.org/10.1038/s41582-018-0058-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10875-013-9965-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037094910", 
              "https://doi.org/10.1007/s10875-013-9965-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10654-015-0094-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011847985", 
              "https://doi.org/10.1007/s10654-015-0094-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-017-08314-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091142962", 
              "https://doi.org/10.1038/s41598-017-08314-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc13699", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030127402", 
              "https://doi.org/10.1186/cc13699"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-018-4862-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1105141735", 
              "https://doi.org/10.1007/s10549-018-4862-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2202-8-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050272084", 
              "https://doi.org/10.1186/1471-2202-8-2"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-10-18", 
        "datePublishedReg": "2021-10-18", 
        "description": "Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barr\u00e9 syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s13311-021-01136-0", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1294839", 
            "issn": [
              "1933-7213", 
              "1878-7479"
            ], 
            "name": "Neurotherapeutics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }
        ], 
        "keywords": [
          "chronic inflammatory demyelinating polyradiculoneuropathy", 
          "hereditary transthyretin-related amyloidosis", 
          "response biomarkers", 
          "disease activity", 
          "nerve damage", 
          "longitudinal disease activity", 
          "inflammatory demyelinating polyradiculoneuropathy", 
          "Guillain-Barr\u00e9 syndrome", 
          "long-term disability", 
          "transthyretin-related amyloidosis", 
          "demyelinating polyradiculoneuropathy", 
          "vasculitic neuropathy", 
          "exploratory endpoints", 
          "clinical symptoms", 
          "fluid biomarkers", 
          "treatment outcomes", 
          "neurofilament light", 
          "additional biomarkers", 
          "clinical care", 
          "clinical practice", 
          "neurological disorders", 
          "clinical tool", 
          "limited evidence", 
          "biomarkers", 
          "trials", 
          "responsive tool", 
          "neuropathy", 
          "polyneuropathy", 
          "most evidence", 
          "NFL", 
          "polyradiculoneuropathy", 
          "patients", 
          "syndrome", 
          "symptoms", 
          "amyloidosis", 
          "damage", 
          "endpoint", 
          "serum", 
          "care", 
          "disorders", 
          "evidence", 
          "outcomes", 
          "disability", 
          "treatment", 
          "activity", 
          "study", 
          "protein", 
          "role", 
          "better understanding", 
          "review", 
          "present time", 
          "high-throughput technologies", 
          "structural changes", 
          "analytical platform", 
          "changes", 
          "bioassay", 
          "use", 
          "candidates", 
          "practice", 
          "future development", 
          "tool", 
          "literature", 
          "promising candidate", 
          "development", 
          "adequality", 
          "time", 
          "discovery", 
          "overview", 
          "understanding", 
          "emergence", 
          "values", 
          "form", 
          "relation", 
          "sensitive analytical platform", 
          "appropriate design", 
          "light", 
          "design", 
          "implementation", 
          "potential applications", 
          "platform", 
          "applications", 
          "technology", 
          "dynamics", 
          "ultrasensitive blood bioassays", 
          "blood bioassays", 
          "useful response biomarkers", 
          "polyneuropathy clinical care", 
          "role of NfL"
        ], 
        "name": "Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials", 
        "pagination": "1-17", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1141955389"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s13311-021-01136-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34661878"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s13311-021-01136-0", 
          "https://app.dimensions.ai/details/publication/pub.1141955389"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T19:02", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_910.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s13311-021-01136-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01136-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01136-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01136-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01136-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    234 TRIPLES      22 PREDICATES      126 URIs      104 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s13311-021-01136-0 schema:about anzsrc-for:11
    2 anzsrc-for:1109
    3 schema:author Nbca48bb31bce430083c06e6049a8e39b
    4 schema:citation sg:pub.10.1007/s00415-021-10537-2
    5 sg:pub.10.1007/s10072-012-1092-z
    6 sg:pub.10.1007/s10549-018-4862-3
    7 sg:pub.10.1007/s10654-015-0094-6
    8 sg:pub.10.1007/s10875-013-9965-3
    9 sg:pub.10.1038/s41582-018-0058-z
    10 sg:pub.10.1038/s41598-017-08314-1
    11 sg:pub.10.1038/s41598-018-37572-w
    12 sg:pub.10.1038/s41598-020-64511-5
    13 sg:pub.10.1038/s41598-020-66815-y
    14 sg:pub.10.1038/s41598-021-90639-z
    15 sg:pub.10.1186/1471-2202-8-2
    16 sg:pub.10.1186/cc13699
    17 sg:pub.10.1186/s13195-021-00841-4
    18 schema:datePublished 2021-10-18
    19 schema:datePublishedReg 2021-10-18
    20 schema:description Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation.
    21 schema:genre article
    22 schema:inLanguage en
    23 schema:isAccessibleForFree true
    24 schema:isPartOf sg:journal.1294839
    25 schema:keywords Guillain-Barré syndrome
    26 NFL
    27 activity
    28 additional biomarkers
    29 adequality
    30 amyloidosis
    31 analytical platform
    32 applications
    33 appropriate design
    34 better understanding
    35 bioassay
    36 biomarkers
    37 blood bioassays
    38 candidates
    39 care
    40 changes
    41 chronic inflammatory demyelinating polyradiculoneuropathy
    42 clinical care
    43 clinical practice
    44 clinical symptoms
    45 clinical tool
    46 damage
    47 demyelinating polyradiculoneuropathy
    48 design
    49 development
    50 disability
    51 discovery
    52 disease activity
    53 disorders
    54 dynamics
    55 emergence
    56 endpoint
    57 evidence
    58 exploratory endpoints
    59 fluid biomarkers
    60 form
    61 future development
    62 hereditary transthyretin-related amyloidosis
    63 high-throughput technologies
    64 implementation
    65 inflammatory demyelinating polyradiculoneuropathy
    66 light
    67 limited evidence
    68 literature
    69 long-term disability
    70 longitudinal disease activity
    71 most evidence
    72 nerve damage
    73 neurofilament light
    74 neurological disorders
    75 neuropathy
    76 outcomes
    77 overview
    78 patients
    79 platform
    80 polyneuropathy
    81 polyneuropathy clinical care
    82 polyradiculoneuropathy
    83 potential applications
    84 practice
    85 present time
    86 promising candidate
    87 protein
    88 relation
    89 response biomarkers
    90 responsive tool
    91 review
    92 role
    93 role of NfL
    94 sensitive analytical platform
    95 serum
    96 structural changes
    97 study
    98 symptoms
    99 syndrome
    100 technology
    101 time
    102 tool
    103 transthyretin-related amyloidosis
    104 treatment
    105 treatment outcomes
    106 trials
    107 ultrasensitive blood bioassays
    108 understanding
    109 use
    110 useful response biomarkers
    111 values
    112 vasculitic neuropathy
    113 schema:name Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials
    114 schema:pagination 1-17
    115 schema:productId N0396e3c72d4345be965188ccb2500f02
    116 Na985ab9b26524f359ab904c6c0144654
    117 Nd13979b0615940789f537ceb023cf87b
    118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141955389
    119 https://doi.org/10.1007/s13311-021-01136-0
    120 schema:sdDatePublished 2022-01-01T19:02
    121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    122 schema:sdPublisher Ne6b5f3435bf74d64aadff98288a8c919
    123 schema:url https://doi.org/10.1007/s13311-021-01136-0
    124 sgo:license sg:explorer/license/
    125 sgo:sdDataset articles
    126 rdf:type schema:ScholarlyArticle
    127 N0396e3c72d4345be965188ccb2500f02 schema:name doi
    128 schema:value 10.1007/s13311-021-01136-0
    129 rdf:type schema:PropertyValue
    130 N1c6ac3f2245e4f9d9d75c3b63d2ef511 rdf:first sg:person.0634111633.10
    131 rdf:rest N75b9021aaec648da9ba9db71c7965226
    132 N40f7169dbac94972914b7b7c0712f78d rdf:first sg:person.013434667454.77
    133 rdf:rest N1c6ac3f2245e4f9d9d75c3b63d2ef511
    134 N75b9021aaec648da9ba9db71c7965226 rdf:first sg:person.01113740141.22
    135 rdf:rest rdf:nil
    136 Na985ab9b26524f359ab904c6c0144654 schema:name dimensions_id
    137 schema:value pub.1141955389
    138 rdf:type schema:PropertyValue
    139 Nb66a1b9ce67a4ffc929157e647326592 rdf:first sg:person.016020033434.82
    140 rdf:rest N40f7169dbac94972914b7b7c0712f78d
    141 Nbca48bb31bce430083c06e6049a8e39b rdf:first sg:person.01221612201.48
    142 rdf:rest Nb66a1b9ce67a4ffc929157e647326592
    143 Nd13979b0615940789f537ceb023cf87b schema:name pubmed_id
    144 schema:value 34661878
    145 rdf:type schema:PropertyValue
    146 Ne6b5f3435bf74d64aadff98288a8c919 schema:name Springer Nature - SN SciGraph project
    147 rdf:type schema:Organization
    148 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    149 schema:name Medical and Health Sciences
    150 rdf:type schema:DefinedTerm
    151 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
    152 schema:name Neurosciences
    153 rdf:type schema:DefinedTerm
    154 sg:journal.1294839 schema:issn 1878-7479
    155 1933-7213
    156 schema:name Neurotherapeutics
    157 schema:publisher Springer Nature
    158 rdf:type schema:Periodical
    159 sg:person.01113740141.22 schema:affiliation grid-institutes:grid.484519.5
    160 schema:familyName Teunissen
    161 schema:givenName Charlotte E.
    162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113740141.22
    163 rdf:type schema:Person
    164 sg:person.01221612201.48 schema:affiliation grid-institutes:grid.484519.5
    165 schema:familyName Wieske
    166 schema:givenName Luuk
    167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221612201.48
    168 rdf:type schema:Person
    169 sg:person.013434667454.77 schema:affiliation grid-institutes:grid.83440.3b
    170 schema:familyName Lunn
    171 schema:givenName Michael P.
    172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013434667454.77
    173 rdf:type schema:Person
    174 sg:person.016020033434.82 schema:affiliation grid-institutes:grid.83440.3b
    175 schema:familyName Smyth
    176 schema:givenName Duncan
    177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016020033434.82
    178 rdf:type schema:Person
    179 sg:person.0634111633.10 schema:affiliation grid-institutes:grid.484519.5
    180 schema:familyName Eftimov
    181 schema:givenName Filip
    182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634111633.10
    183 rdf:type schema:Person
    184 sg:pub.10.1007/s00415-021-10537-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136872557
    185 https://doi.org/10.1007/s00415-021-10537-2
    186 rdf:type schema:CreativeWork
    187 sg:pub.10.1007/s10072-012-1092-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1030217645
    188 https://doi.org/10.1007/s10072-012-1092-z
    189 rdf:type schema:CreativeWork
    190 sg:pub.10.1007/s10549-018-4862-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105141735
    191 https://doi.org/10.1007/s10549-018-4862-3
    192 rdf:type schema:CreativeWork
    193 sg:pub.10.1007/s10654-015-0094-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011847985
    194 https://doi.org/10.1007/s10654-015-0094-6
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1007/s10875-013-9965-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037094910
    197 https://doi.org/10.1007/s10875-013-9965-3
    198 rdf:type schema:CreativeWork
    199 sg:pub.10.1038/s41582-018-0058-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1106465735
    200 https://doi.org/10.1038/s41582-018-0058-z
    201 rdf:type schema:CreativeWork
    202 sg:pub.10.1038/s41598-017-08314-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091142962
    203 https://doi.org/10.1038/s41598-017-08314-1
    204 rdf:type schema:CreativeWork
    205 sg:pub.10.1038/s41598-018-37572-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1111775406
    206 https://doi.org/10.1038/s41598-018-37572-w
    207 rdf:type schema:CreativeWork
    208 sg:pub.10.1038/s41598-020-64511-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1127595131
    209 https://doi.org/10.1038/s41598-020-64511-5
    210 rdf:type schema:CreativeWork
    211 sg:pub.10.1038/s41598-020-66815-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1128483154
    212 https://doi.org/10.1038/s41598-020-66815-y
    213 rdf:type schema:CreativeWork
    214 sg:pub.10.1038/s41598-021-90639-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1138362468
    215 https://doi.org/10.1038/s41598-021-90639-z
    216 rdf:type schema:CreativeWork
    217 sg:pub.10.1186/1471-2202-8-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050272084
    218 https://doi.org/10.1186/1471-2202-8-2
    219 rdf:type schema:CreativeWork
    220 sg:pub.10.1186/cc13699 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030127402
    221 https://doi.org/10.1186/cc13699
    222 rdf:type schema:CreativeWork
    223 sg:pub.10.1186/s13195-021-00841-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138157330
    224 https://doi.org/10.1186/s13195-021-00841-4
    225 rdf:type schema:CreativeWork
    226 grid-institutes:grid.484519.5 schema:alternateName Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands
    227 Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands
    228 schema:name Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands
    229 Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands
    230 rdf:type schema:Organization
    231 grid-institutes:grid.83440.3b schema:alternateName UCL Queen Square Institute of Neurology, London, UK
    232 schema:name Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, UK
    233 UCL Queen Square Institute of Neurology, London, UK
    234 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...